were studied. Erlotinib and bortezomib were also included.
The clinical relevance of the particular agents selected is unclear given the lack of single agent activity in recurrent adult gliomas with the exception of TMZ. GSC are relatively quiescent, radiation-and chemotherapy-resistant, multi-potent, and able to self-renew. Reply from the Authors We proposed an in vitro approach to evaluate chemotherapeutics as potential treatments for glioblastomas. We also attempted to investigate potential causes of damage to endogenous neural stem cells (NSCs), which are responsible for maintaining active neurogenesis in the adult brain.
[1]
The choice of chemotherapeutics for our initial studies was based on drugs most commonly used in neuro-oncology and also those used in general oncology. This is because drugs used for non-nervous system tumors may still have significant nervous system effects. For example, although the platinum adduct agents are widely used for treatment in a variety of cancers, a current search of the clinicaltrial.gov database identifies more than one hundred studies using cisplatin or carboplatin for the treatment of CNS malignancies. Moreover, the proteasome inhibitors are now integral to multiple myeloma treatment, while the epidermal growth factor receptor tyrosine kinase inhibitors are widely used in the treatment of lung cancer.
Since the established treatment for malignant gliomas includes radiation and chemotherapy with temozolomide, it is hard to ascribe the cognitive damage our patients experienced to just one of these modalities. This underscores the need to model treatment toxicity in both in vivo and in vitro models.
Although the lack of correlation between MGMT levels, the mismatch repair system, and the NSC response to temozolomide may seem counterintuitive, there are other, multiple genes involved in TMZ resistances including several genes involved in differentiation. [3] These complexities aside, Abcg2-a multidrug resistance gene which we found to have a lower expression in NSCs than in glioma stem-like cells (GSCs)-has been shown to be involved in cisplatin resistance in other cancers [4] , and higher Abcg2 expression was reported in TMZ-resistant GSCs. [5] Although none of the chemotherapeutics we tested, with the exception of temozolomide, has single activity in malignant gliomas, our data suggest that erlotinib and bortezomib have the ability to preferentially target GSCs, even though a subpopulation of GSCs displayed resistance to even high-doses of these targeted drugs. This is not a "failure of in vitro chemosensitivity assays to predict in vivo responses", but rather points to a need to intelligently design a treatment cocktail for the malignant gliomas that target cells in different stages of differentiation.
The differential toxicity of chemotherapy for different neural cell populations at various stages of development still warrants investigation. Although adult NSCs can be harvested and cultured, they are usually generated from anterior temporal lobe resections taken from epilepsy patients who received multiple drug treatments known to affect neurogenesis.
[6] The NSCs we used, although neither embryonic nor adult but preserved from newborns [7] , has been established as the most reliable source of normal NSCs.
